Correction: Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

• Ho Jin Lee,
• Phuong Chi Pham,
• Seung Yeob Hyun,
• Byungyeob Baek,
• Byungjin Kim,
• Yunha Kim,
• Hye-Young Min,
• Jeeyeon Lee,
• Ho-Young Lee

Affiliations

Ho Jin Lee

Creative Research Initiative Center for Concurrent Control of Emphysema and Lung Cancer, College of Pharmacy, Seoul National University

Phuong Chi Pham

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University

Seung Yeob Hyun

Creative Research Initiative Center for Concurrent Control of Emphysema and Lung Cancer, College of Pharmacy, Seoul National University

Byungyeob Baek

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University

Byungjin Kim

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University

Yunha Kim

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University

Hye-Young Min

Creative Research Initiative Center for Concurrent Control of Emphysema and Lung Cancer, College of Pharmacy, Seoul National University

Jeeyeon Lee

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University

Ho-Young Lee

Creative Research Initiative Center for Concurrent Control of Emphysema and Lung Cancer, College of Pharmacy, Seoul National University